Health and wellness

Warm autoimmune hemolytic anemia is a rare, life-threatening disease that causes intense fatigue. Johnson & Johnson has a new therapy that targets the underlying drivers of the disease. Here, two patients—and Johnson & Johnson employees—share their journey, from symptoms and diagnosis to managing work and personal life.

This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and how Johnson & Johnson is innovating across both early-stage and advanced disease.

Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and Johnson & Johnson’s clinical research and ongoing commitment to patients.

For 25 years, Johnson & Johnson has pursued innovative blood cancer treatments. Scientist Kodandaram “Ram” Pillarisetti has helped shape that pursuit, from discovering a target that led to an approved bispecific therapy to research exploring a next-generation trispecific antibody approach.

It’s the most common type of acute leukemia in adults, yet it has the lowest survival rate of all leukemias. Learn more about this difficult-to-treat blood cancer and why Johnson & Johnson is on a mission to deliver better treatment options.

Only one in three people with major depressive disorder achieves remission after their first antidepressant, leaving many to continue to experience life-impacting symptoms such as disrupted sleep, changes in weight and appetite and trouble concentrating. Learn why Johnson & Johnson is working to help more patients achieve remission.

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

Diagnosed with systemic lupus erythematosus (SLE) almost two decades ago, Laurie Bean has chosen a lifestyle that helps her battle debilitating side effects and the emotional fallout of this autoantibody disease.

From using cutting-edge technology to address mental health issues to launching an urban clinic that helps treat substance-abuse disorders and taking an innovative approach to deliver rural medical care, learn how Johnson & Johnson is helping support a new generation of providers.